-
Journal of Clinical Pharmacology Dec 2006Anticholinergic Drug Scale (ADS) scores were previously associated with serum anticholinergic activity (SAA) in a pilot study. To replicate these results, the... (Clinical Trial)
Clinical Trial
Anticholinergic Drug Scale (ADS) scores were previously associated with serum anticholinergic activity (SAA) in a pilot study. To replicate these results, the association between ADS scores and SAA was determined using simple linear regression in subjects from a study of delirium in 201 long-term care facility residents who were not included in the pilot study. Simple and multiple linear regression models were then used to determine whether the ADS could be modified to more effectively predict SAA in all 297 subjects. In the replication analysis, ADS scores were significantly associated with SAA (R2 = .0947, P < .0001). In the modification analysis, each model significantly predicted SAA, including ADS scores (R2 = .0741, P < .0001). The modifications examined did not appear useful in optimizing the ADS. This study replicated findings on the association of the ADS with SAA. Future work will determine whether the ADS is clinically useful for preventing anticholinergic adverse effects.
Topics: Aged; Aged, 80 and over; Binding, Competitive; Cholinergic Antagonists; Cross-Sectional Studies; Delirium; Female; Humans; Linear Models; Long-Term Care; Male; Middle Aged; Prospective Studies; Radioligand Assay; Time Factors
PubMed: 17101747
DOI: 10.1177/0091270006292126 -
Progres En Urologie : Journal de... Sep 2019
Topics: Cholinergic Antagonists; Humans; Urinary Bladder, Overactive
PubMed: 31351806
DOI: 10.1016/j.purol.2019.06.007 -
Neuro-degenerative Diseases 2015In this article, we review the downregulation of acetylcholinergic activity in schizophrenia and discuss the similarity and difference between Alzheimer's disease (AD)... (Review)
Review
In this article, we review the downregulation of acetylcholinergic activity in schizophrenia and discuss the similarity and difference between Alzheimer's disease (AD) and schizophrenia in terms of acetylcholine (ACh) and anticholinergic activity (AA); then, we propose the use of cognition-enhancing therapy for schizophrenia. As ACh regulates an inflammatory system, when the cholinergic system is downregulated to a critical level, the inflammatory system is activated. We consider the possibility that AA appears endogenously in AD and accelerates AD pathology. This hypothesis can also be applied to schizophrenia. In fact, even before the onset of the disorder, in the prodromal phase of schizophrenia, cognitive dysfunction exists, and antibodies against astrocyte muscarinic-1 and muscarinic-2 receptors are present in the serum of patients with the paranoid type of schizophrenia. Then we noted that the prodromal phase in schizophrenia might correspond to the mild stage in AD and the acute phase to moderate stage concerning AA. We also think that we should enhance cognition in schizophrenia even in the prodromal phase because as mentioned above, downregulation of ACh is prominent in schizophrenia even in the prodromal phase.
Topics: Animals; Cholinergic Antagonists; Humans; Schizophrenia
PubMed: 26138495
DOI: 10.1159/000381523 -
Drugs Dec 2020Sofpironium bromide (ECCLOCK in Japan) gel is a topical anticholinergic agent developed by Bodor Laboratories and licenced to Brickell Biotech for the treatment of... (Review)
Review
Sofpironium bromide (ECCLOCK in Japan) gel is a topical anticholinergic agent developed by Bodor Laboratories and licenced to Brickell Biotech for the treatment of hyperhidrosis. The drug is designed to reduce sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. In September 2020, sofpironium bromide gel 5% received its first approval in Japan for the treatment of primary axillary hyperhidrosis (PAH). Clinical studies are currently ongoing in the USA to assess the safety and efficacy of sofpironium bromide gel 15% in PAH. This article summarizes the milestones in the development of sofpironium bromide gel leading to this first approval for the treatment of PAH.
Topics: Bromides; Cholinergic Antagonists; Gels; Humans; Hyperhidrosis; Japan
PubMed: 33236266
DOI: 10.1007/s40265-020-01438-1 -
The Cochrane Database of Systematic... 2001Anticholinergic agents block bronchoconstriction mediated by the vagus nerve and may also dry up bronchial secretions. They are effective in obstructive airways disease... (Review)
Review
BACKGROUND
Anticholinergic agents block bronchoconstriction mediated by the vagus nerve and may also dry up bronchial secretions. They are effective in obstructive airways disease and may be beneficial in bronchiectasis
OBJECTIVES
To determine the effect of anticholinergic therapy in acute exacerbations and stable bronchiectasis.
SEARCH STRATEGY
The Cochrane Airways Group clinical trials register was searched using the terms bronchiectasis AND anticholinergic OR ipratropium bromide OR tiotropium OR atropine.
SELECTION CRITERIA
Only randomised controlled trials were considered.
DATA COLLECTION AND ANALYSIS
Two reviewers assessed the retrieved studies working independently.
MAIN RESULTS
Twelve studies were identified, of which six were obtained for further scrutiny. One was translated from Italian. None met the inclusion criteria.
REVIEWER'S CONCLUSIONS
No formal recommendations can be made about the use of anticholinergic therapy in acute or stable bronchiectasis based on the literature currently available.
Topics: Acute Disease; Bronchiectasis; Cholinergic Antagonists; Humans
PubMed: 11687147
DOI: 10.1002/14651858.CD002163 -
BMJ (Clinical Research Ed.) Apr 2018
Topics: Age Factors; Aged; Aged, 80 and over; Cholinergic Antagonists; Contraindications; Dementia; Dose-Response Relationship, Drug; Humans; Risk Assessment
PubMed: 29695471
DOI: 10.1136/bmj.k1722 -
Expert Opinion on Pharmacotherapy Nov 2005The combination of an alpha1-blocker with an anticholinergic is a new and promising therapeutic approach for bladder outlet obstruction and detrusor overactivity. Both... (Comparative Study)
Comparative Study Review
Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction.
The combination of an alpha1-blocker with an anticholinergic is a new and promising therapeutic approach for bladder outlet obstruction and detrusor overactivity. Both placebo-controlled and comparative studies have demonstrated that the addition of an anticholinergic in the conventional treatment of patients with bladder outlet obstruction is safe, as the likelihood of acute urinary retention is low. Although the pathophysiology of detrusor overactivity is unknown and most probably multifactorial, it is not expected that the voiding phase is influenced by regular doses of anticholinergics, although high doses may affect detrusor contraction. However, safety issues must be studied further. The combination of tamsulosin with propiverine or tolterodine, and of doxasosin with tolterodine has been shown to cause a significant improvement of lower urinary tract symptoms when compared with alpha1-blocker monotherapy. Indisputably, the existing literature provides clear evidence that the combination of an alpha1-blocker with an anticholinergic extends physicians ability to manage lower urinary tract symptoms caused by bladder outlet obstruction and overactive bladder syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Benzhydryl Compounds; Benzilates; Cholinergic Antagonists; Cresols; Doxazosin; Drug Therapy, Combination; Humans; Male; Phenylpropanolamine; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Urinary Bladder Neck Obstruction; Urinary Incontinence; Urodynamics; Urologic Diseases
PubMed: 16259574
DOI: 10.1517/14656566.6.14.2429 -
Clinical Interventions in Aging 2014The effects of an anticholinergic or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms (LUTS) according to a voiding diary in 3... (Randomized Controlled Trial)
Randomized Controlled Trial
Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms.
PURPOSE
The effects of an anticholinergic or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms (LUTS) according to a voiding diary in 3 days are unknown. We prospectively investigated the efficacy of an anticholinergic or antidiuretic agent as add-on therapy for nocturia in men previously treated with an alpha-blocker for LUTS.
SUBJECTS AND METHODS
Patients were randomly subdivided into two groups. All patients had a 4-week washout. Group A had alpha-blocker for 4 weeks, then an alpha-blocker plus an anticholinergic agent for 4 weeks, and, finally, 4 weeks of an alpha-blocker plus an antidiuretic agent. Group B had an alpha-blocker for 4 weeks, then an alpha-blocker plus an antidiuretic agent for 4 weeks, and, finally, 4 weeks of an alpha-blocker plus an anticholinergic agent. In both groups, patients were subdivided into nocturnal polyuria, decreased nocturnal bladder capacity (NBC), or nocturia by both causes subgroups. A 3-day voiding diary, total International Prostate Symptom Score (IPSS), IPSS sub-scores, Overactive Bladder Symptom Score, uroflowmetry, and post-void residual urine volume, were assessed at baseline, and at 4, 8, and 12 weeks.
RESULTS
A total of 405 patients completed the study. During treatment, the changes from baseline in total IPSS and IPSS sub-scores were significantly decreased at 4 weeks and were maintained for 12 weeks. In the nocturnal polyuria subgroup of Groups A and B, the number of episodes of nocturia in 3 days, nocturnal urine volume, and nocturnal index were significantly decreased using an alpha-blocker plus an antidiuretic agent. In the decreased NBC subgroup of Groups A and B, IPSS storage sub-score, Overactive Bladder Symptom Score, number of episodes of nocturia in 3 days, number of episodes of urgency in 3 days, and NBC index were all significantly decreased using an alpha-blocker plus an anticholinergic agent.
CONCLUSION
An anticholinergic agent or antidiuretic agent as an add-on therapy in men previously treated with an alpha-blocker improves nocturia including LUTS.
Topics: Adrenergic alpha-Antagonists; Aged; Antidiuretic Agents; Cholinergic Antagonists; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Nocturia; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive
PubMed: 25031529
DOI: 10.2147/CIA.S64194 -
BMJ (Clinical Research Ed.) Sep 2023
Topics: Humans; Aged; Cholinergic Antagonists; Cardiovascular Diseases
PubMed: 37758269
DOI: 10.1136/bmj.p2133 -
Journal of UOEH 2019Constipation is very common and can be caused by adverse drug reactions as a result of many drugs. While the adverse effects of several medications such as opioids and... (Review)
Review
Constipation is very common and can be caused by adverse drug reactions as a result of many drugs. While the adverse effects of several medications such as opioids and anticholinergic agents are well established and well known, other commonly prescribed drugs, such as hypnotics, are less well understood. This review presents the results of an analysis of the relationship between constipation and drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents, Tricyclic; Calcium Channel Blockers; Cholinergic Antagonists; Constipation; Diuretics; Histamine Antagonists; Humans; Hypnotics and Sedatives; Opioid-Induced Constipation; Parasympatholytics
PubMed: 31292358
DOI: 10.7888/juoeh.41.145